Floatz logo

Fulzerasib

KRAS G12C

Innovent Biologics (Suzhou) Co. Ltd.Small moleculePhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
81/ 100

Competitive context

23 Active assets in the KRAS G12C cohort.

Asset / SponsorPhaseRating
Sotorasib
ETOP IBCSG Partners Foundation
Phase 2CCC
Adagrasib
Ryan Gentzler, MD
Phase 2CCC
LENVATINIB
ETOP IBCSG Partners Foundation
Phase 2CCC
Opnurasib
Maastricht University Medical Center
Phase 2CCC
Fmc-376
Frontier Medicines Corporation
Phase 1/2CC

View all 23 →

Same molecule, other indications

Fulzerasib is also rated in:

non-small cell lung carcinomaDormant
BB
Indicative ·
70 / 100
View asset →
KRAS G12C Mutant Advanced Solid TumorsDormant
CCC
Indicative ·
53 / 100
View asset →
FulzerasibDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →